Table 2.
Number of participants in the cohort study who could potentially meet the criteria of fertility impairment by participating cohort.
| Name of study cohort | Criterion 1 (n=1455) | Criterion 2 (n=1566) | Criterion 3 (n=1207) | Criterion 4 (n=3133) | Criterion 5 (n=5861) | Criterion 6 (n=1640) | Criterion 7 (n=2759) | Criterion 8 (n=5050) | |||||||||
| DCOG LATER cohort | 615 | 615 | 614 | 1109 | 1109 | 619 | 1109 | 0 | |||||||||
| Hodgkin Lymphoma cohort | 0 | 0 | 0 | 203 | 203 | 0 | 0 | 0 | |||||||||
| VIVE cohort | 0 | 0 | 0 | 0 | 2482 | 0 | 0 | 2482 | |||||||||
| Ewing 2008 Clinical Trials cohort | 22 | 22 | 2 | 46 | 46 | 24 | 46 | 46 | |||||||||
| Berlin Hormone Analyses cohort | 69 | 69 | 69 | 83 | 83 | 69 | 0 | 0 | |||||||||
| Cohort female 5-y cancer survivors Brno | 180 | 180 | 85 | 182 | 182 | 180 | 182 | 182 | |||||||||
| Cohort female 5-y cancer survivors Motole | 236 | 236 | 198 | 574 | 574 | 301 | 574 | 574 | |||||||||
| Swiss Childhood Cancer Registry cohort 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 685 | |||||||||
| Swiss Childhood Cancer Registry cohort 2 | 0 | 0 | 0 | 0 | 113 | 0 | 0 | 113 | |||||||||
| Lymphoma survivor cohort | 0 | 46 | 36 | 0 | 51 | 46 | 51 | 51 | |||||||||
| Acute lymphoblastic leukemia survivor cohort | 0 | 65 | 10 | 0 | 82 | 65 | 82 | 82 | |||||||||
| Rhone Alpe cohort 1 | 35 | 35 | 9 | 120 | 120 | 35 | 0 | 120 | |||||||||
| Rhone Alpe cohort 2 | 62 | 62 | 0 | 101 | 101 | 62 | 0 | 0 | |||||||||
| Gaslini female survivors cohort | 122 | 122 | 109 | 563 | 563 | 122 | 563 | 563 | |||||||||
| Hematopoietic stem cell transplantation cohort | 42 | 42 | 40 | 50 | 50 | 44 | 50 | 50 | |||||||||
| The Edmond and Lily Safra Children’s Hospital Late Effects cohort | 72 | 72 | 35 | 102 | 102 | 73 | 102 | 102 | |||||||||